T1	Participants 322 502	Fifty-six patients (49 boys, 7 girls, mean age = 6.4 years, SD = 2.7) enrolled in an open-label trial of secretin, during which they received one injection of the hormone (2 IU/kg)
T2	Participants 820 882	Forty-five patients were concurrently on other drug treatments
T3	Participants 1425 1529	Patients from Study 1 entered into Study 2 at an average of 6.5 (SD = 0.8) weeks after beginning Study 1
T4	Participants 1271 1423	Patients in this second study were alternatively entered into one of two groups and received injections of secretin or placebo with crossover at 4 weeks
